# Hematologic Neoplasms trials: 192 new since Nov 2024

Updated November 9, 2026.

192 clinical studies in Hematologic Neoplasms were first posted on ClinicalTrials.gov from November 13, 2024 to November 9, 2026; 43 have an industry sponsor and 161 are recruiting or about to. The newest, NCT07926698, was posted on November 9, 2026: Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A... (The First Affiliated Hospital of Soochow University).

## The full list

New Hematologic Neoplasms clinical trials: 192 rows for $9.60, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/hematologic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 192
- Industry sponsored: 43
- Recruiting or not yet: 161
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 192, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926698 | Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm... | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation, Acute Graft-Versus-Host Disease | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926698) |
| November 9, 2026 | NCT07926217 | High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy | Sung-Han Kim | Phase 2 | Recruiting | Hematologic Malignancy, Influenza | 60 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926217) |
| November 6, 2026 | NCT07923162 | MACE and BTK Inhibitors | University Hospital, Caen | Phase 4 | Not yet recruiting | Hematologic Cancer, MACE, BTK Inhibitors | 10,000 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923162) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| October 28, 2026 | NCT07900542 | Middle East Study of Infections in Patients With Hematological Malignancies | Hamad Medical Corporation | Observational | Recruiting | Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Bloodstream Infection | 1,000 | Jordan, Oman, Qatar, Saudi Arabia, United Arab Emirates | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900542) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 26, 2026 | NCT07895693 | Comprehensive Palliative Care After Stem Cell Transplantation: a Feasability Study | Lisa Hentsch | Not applicable | Recruiting | Hematopoietic Stem Cell Transplantation (HSCT) | 42 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895693) |
| October 26, 2026 | NCT07894601 | Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients | Fundación para la Investigación del Hospital Clínico de Valencia | Not applicable | Recruiting | Hematologic Cancer | 145 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894601) |
| October 23, 2026 | NCT07891533 | Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera | AN2 Therapeutics, Inc | Phase 2 | Not yet recruiting | Polycythemia Vera (SNOMED CT: 109992005) | 75 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891533) |
| October 21, 2026 | NCT07886190 | Symptom Monitoring and Management Intervention After CAR-T | Massachusetts General Hospital | Not applicable | Not yet recruiting | Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy | 65 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886190) |
| October 14, 2026 | NCT07873827 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | Stemline Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | Hematological Malignancy | 115 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873827) |
| October 14, 2026 | NCT07872813 | Effects of Resistance Training on Recovery During Hematopoietic Stem Cell Transplantation | Taipei Veterans General Hospital, Taiwan | Not applicable | Not yet recruiting | Hematologic Malignancies, Hematopoietic Stem Cell Transplantation, Resistance Training, Neutropenia, Acute... | 86 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872813) |
| October 7, 2026 | NCT07864467 | BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry | South Tees Hospitals NHS Foundation Trust | Observational | Not yet recruiting | Cancer and / or Hematological Malignancy, Anthracycline-induced Cardiotoxicity | 200 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864467) |
| October 6, 2026 | NCT07861971 | Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission | Institut Paoli-Calmettes | Observational | Recruiting | Solid and Hematologic Cancer | 19 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861971) |
| October 6, 2026 | NCT07861620 | Animal-Assisted Intervention for Children With Cancer and Their Siblings | Azienda Ulss 2 Marca Trevigiana | Not applicable | Completed | Hematologic Neoplasms, Neoplasms | 50 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861620) |
| October 6, 2026 | NCT07861477 | Murottal as Adjunctive Intervention in Pediatric | Universitas Airlangga | Not applicable | Completed | Pediatric Cancer, Hematologic Malignancies, Anxiety, Sleep Disturbances in Children, Leukemia (Both ALL and AML) | 20 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861477) |
| September 29, 2026 | NCT07845669 | Effects of Synbiotic Supplementation on Gastrointestinal Symptoms, Appetite, and Nutritional Recovery in Patients After Autologous Bone... | Alexandria University | Not applicable | Not yet recruiting | Hematologic Neoplasms, Gastrointestinal Symptoms, Malnutrition, Loss of Appetite, Anorexia, Dysbiosis | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845669) |
| September 25, 2026 | NCT07842679 | Cognitive Impairment in Older Adults With Hematologic Malignancies | Assiut University | Observational | Not yet recruiting | Cognitive Impairment, Hematologic Malignancies, Chemotherapy Effect | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842679) |
| September 17, 2026 | NCT07825714 | Metagenomic Sequencing Across the Infectious Disease Risk and Care Continuum | Karius, Inc. | Observational | Not yet recruiting | Infectious Diseases, Immunocompromised Host, Opportunistic Infections | 10,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825714) |
| September 10, 2026 | NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | University of West Attica | Not applicable | Active not recruiting | Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant, Psychological Trauma, Neoplasms, Hematological Malignancies... | 80 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814170) |
| September 9, 2026 | NCT07809906 | Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression | Orum Therapeutics USA, Inc. | Phase 1 | Recruiting | CD123+ Acute Myeloid Leukemia | 42 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809906) |
| September 9, 2026 | NCT07809139 | A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies | Nanjing Miracle Biotechnology Co., Ltd. | Phase 1 | Not yet recruiting | Hematological Malignancies | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809139) |
| September 9, 2026 | NCT07809126 | A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in... | Nanjing Miracle Biotechnology Co., Ltd. | Phase 1 | Not yet recruiting | Hematological Malignancies | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809126) |
| September 8, 2026 | NCT07808112 | CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell... | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Graft -Versus-host-disease | 72 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808112) |
| September 3, 2026 | NCT07802756 | Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies | Suzhou Immunofoco Biotechnology Co., Ltd | Early phase 1 | Not yet recruiting | Relapsed/Refractory Hematologic Malignancies | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802756) |
| September 3, 2026 | NCT07802015 | Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish Study of Feasibility, Costs, and Implementation | Zealand University Hospital | Observational | Not yet recruiting | Hematologic Cancer, Acute Myeloid Leukaemia (AML), Hospital At Home, Home-based Chemotherapy | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802015) |
| August 25, 2026 | NCT07785505 | Musculoskeletal Ultrasound in Patients With Hematologic Malignancies | Assiut University | Observational | Not yet recruiting | Hematologic Neoplasms, Leukemia, Lymphoma, Multiple Myeloma, Musculoskeletal Diseases | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785505) |
| August 13, 2026 | NCT07763184 | mNGS for IFD in Patients With Hematological Malignancies | Nanfang Hospital, Southern Medical University | Observational | Not yet recruiting | Hematological Malignancies, Invasive Fungal Disease | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763184) |
| August 13, 2026 | NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | Observational | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma, Multiple Myeloma, Chronic... | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763054) |
| August 10, 2026 | NCT07756034 | Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer | Tempus AI | Observational | Recruiting | Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies | 1,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756034) |
| August 7, 2026 | NCT07753148 | Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic... | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS) | 52 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753148) |
| August 4, 2026 | NCT07743476 | Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions | M.D. Anderson Cancer Center | Observational | Recruiting | Hematologic, Oncologic, Bone Marrow | 1,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743476) |
| July 24, 2026 | NCT07724873 | Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients | Tata Memorial Centre | Phase 1/2 | Recruiting | Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy | 54 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724873) |
| July 22, 2026 | NCT07719946 | To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers | Tata Memorial Centre | Phase 2 | Recruiting | Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies | 20 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719946) |
| July 20, 2026 | NCT07714044 | Rutgers University Study of the Genetics of Blood Cancers | Rutgers, The State University of New Jersey | Observational | Recruiting | Blood Cancers, Blood Cancer, Leukemia, Lymphoma, Myeloma, Hematologic Cancer, Hematologic Malignancies, Hematologic... | 10,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714044) |
| July 20, 2026 | NCT07712835 | ECMO Use in Pediatric Oncology and HSCT Patients: A Descriptive and Comparative Analysis | Children's Mercy Hospital Kansas City | Observational | Completed | ECMO Outcomes, Respiratory Failure (Pediatric Patients), Malignancies, Hematologic, Solid Tumor Malignancies... | 22 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712835) |
| July 17, 2026 | NCT07711327 | Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy | Tina Baykaner | Observational | Not yet recruiting | Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal... | 500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711327) |
| July 17, 2026 | NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic... | Ossium Health, Inc. | Not applicable | Not yet recruiting | Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic... | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710781) |
| July 16, 2026 | NCT07709637 | Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients | LucasBio | Phase 1 | Active not recruiting | COVID-19, COVID-19 (SARS-CoV-2 Infection) | 1 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709637) |
| July 16, 2026 | NCT07709195 | Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant | Tata Memorial Centre | Phase 2 | Recruiting | Oral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT) | 17 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709195) |
| July 16, 2026 | NCT07709013 | Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients | Tata Memorial Centre | Phase 2 | Recruiting | Hematologic Malignancies | 22 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709013) |
| July 16, 2026 | NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies | 60 | Colombia, Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709000) |
| July 16, 2026 | NCT07708987 | Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease. | Tata Memorial Centre | Phase 2 | Recruiting | Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory | 34 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708987) |
| July 14, 2026 | NCT07703644 | Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients | Sizhou Feng | Observational | Not yet recruiting | Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae... | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703644) |
| July 8, 2026 | NCT07691008 | Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol | City of Hope Medical Center | Observational | Not yet recruiting | Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm, Hematopoietic and Lymphatic System Neoplasm | 1,200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691008) |
| July 8, 2026 | NCT07689630 | Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 | Recruiting | Graft Versus Host Disease, Hematologic Neoplasms | 186 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689630) |
| July 1, 2026 | NCT07679412 | Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis. | LucasBio | Not applicable | Recruiting | CMV Retinitis | 5 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679412) |
| July 1, 2026 | NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of... | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Not yet recruiting | T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma, Relapsed/Refractory Hematologic Malignancies | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678307) |
| June 29, 2026 | NCT07674212 | Take5Care+: A Self-management Educational Intervention | Jitka Vseteckova | Not applicable | Not yet recruiting | Hematologic Neoplasms | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674212) |
| June 29, 2026 | NCT07672964 | CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation | Ruijin Hospital | Phase 1 | Not yet recruiting | Hematologic Malignancy, Haplo-identical HCT | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672964) |
| June 23, 2026 | NCT07662382 | Cousin vs. Sibling Donors in Haplo-HSCT | The First Affiliated Hospital of Soochow University | Observational | Not yet recruiting | Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation, Donor | 1,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662382) |
| June 23, 2026 | NCT07662369 | CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation | Ruijin Hospital | Phase 1/2 | Recruiting | Hematologic Malignancy, Haplo-identical HCT | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662369) |
| June 17, 2026 | NCT07653672 | Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With... | Centre Hospitalier Annecy Genevois | Observational | Recruiting | Thrombocytopenia, Platelet Transfusion, Haemorrhage, Hematologic Malignancies | 410 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07653672) |
| June 15, 2026 | NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting... | CSL Behring | Phase 3 | Recruiting | Secondary Immune Deficiency | 63 | Belgium, Canada, Czechia, Denmark, France, Germany, Italy, Poland, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648264) |
| June 9, 2026 | NCT07636486 | Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies | Nanfang Hospital, Southern Medical University | Phase 2/3 | Not yet recruiting | Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies | 90 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636486) |
| June 9, 2026 | NCT07635511 | Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies | The First Affiliated Hospital of Soochow University | Phase 3 | Not yet recruiting | Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies | 42 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635511) |
| June 8, 2026 | NCT07634263 | Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study | Odense University Hospital | Observational | Not yet recruiting | Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple... | 50 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634263) |
| June 5, 2026 | NCT07629726 | A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms | Kyowa Kirin Co., Ltd. | Phase 1/2 | Recruiting | Hematologic Neoplasms | 72 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629726) |
| June 2, 2026 | NCT07621887 | Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer | The Hong Kong Polytechnic University | Not applicable | Not yet recruiting | Hematologic Cancer, Leukaemia, Lymphoma, Physical Activity | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621887) |
| June 2, 2026 | NCT07621289 | Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe | University Hospital, Caen | Observational | Not yet recruiting | Cancer, Anticancer Treatment, Cardiovascular Disease Risk Factor, Cardiovascular Diseases, Hematological Malignancies | 10,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621289) |
| May 27, 2026 | NCT07609485 | Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy | University Hospital, Lille | Observational | Recruiting | Cancer, Hematologic Malignancy | 700 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609485) |
| May 26, 2026 | NCT07607379 | Robotic Dog Intervention on Emotional Well-Being and Quality of Life | Koç University | Not applicable | Not yet recruiting | Emotional Well-being, Quality of Life, Pediatric Oncology | 28 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607379) |
| May 15, 2026 | NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Phase 4 | Not yet recruiting | Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors, Invasive Bacterial Infection | 136 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590648) |
| May 11, 2026 | NCT07579065 | HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT | Azienda USL Reggio Emilia - IRCCS | Not applicable | Recruiting | Hematologic Neoplasm, Hematopoietic Stem Cell Transplantation, Survivorship, Cancer Survivorship | 40 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579065) |
| May 7, 2026 | NCT07572006 | A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies | Janssen Research & Development, LLC | Phase 1 | Recruiting | Hematologic Neoplasms | 320 | Australia, Belgium, Denmark, France, Spain, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572006) |
| May 6, 2026 | NCT07570563 | Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Hematologic Malignancy, Solid Tumor | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570563) |
| April 21, 2026 | NCT07541326 | Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France | University Hospital, Limoges | Not applicable | Not yet recruiting | Hematological Malignancies | 85 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541326) |
| April 20, 2026 | NCT07539779 | Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis | Nanfang Hospital, Southern Medical University | Phase 2/3 | Not yet recruiting | Luspatercept, Poor Erythroid Engraftment, Hematological Malignancies, Myelofibrosis (MF) | 196 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539779) |
| April 16, 2026 | NCT07532746 | A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies | Kousai Bio Co., Ltd. | Phase 1 | Not yet recruiting | Relapsed or Refractory EBV-associated Hematological Malignancies | 55 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532746) |
| April 13, 2026 | NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma | 102 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524530) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| April 9, 2026 | NCT07519811 | LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) | Technical University of Munich | Not applicable | Recruiting | Hematologic Neoplasms, Oncologic Disorders | 150 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519811) |
| April 6, 2026 | NCT07511127 | Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT | Ruijin Hospital | Phase 3 | Recruiting | Hematologic Malignancy | 218 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511127) |
| March 31, 2026 | NCT07504458 | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | Quetzal Therapeutics | Phase 3 | Recruiting | Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute... | 150 | France, Italy, Romania, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07504458) |
| March 20, 2026 | NCT07485855 | Influenza Vaccination Strategy for Patients With Hematologic Malignancy | Asan Medical Center | Phase 3 | Recruiting | Hematologic Neoplasms, Influenza, Immunogenicity | 120 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485855) |
| March 20, 2026 | NCT07485504 | Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies | Tcelltech Inc. | Phase 1 | Not yet recruiting | Relapsed or Refractory Hematologic Malignancies | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485504) |
| March 16, 2026 | NCT07474051 | Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials | AvenCell Therapeutics, Inc. | Observational | Enrolling by invitation | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia), Prostate Cancer | 178 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07474051) |
| March 11, 2026 | NCT07463976 | variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway | The Royal Wolverhampton Hospitals NHS Trust | Observational | Not yet recruiting | Chronic Lymphocytic Leukemia, Haematological Malignancy | 130 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463976) |
| March 10, 2026 | NCT07462962 | Effects of Mindfulness Meditation Training on Anxiety and Sleep Quality of Patients With Hematopoietic Stem Cell Transplantation During... | Henan University | Observational | Completed | Hematopoietic Stem Cell Transplantation (HSCT), Cancer and / or Hematological Malignancy | 70 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462962) |
| March 9, 2026 | NCT07456982 | The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting | Marmara University | Not applicable | Active not recruiting | Nausea and Vomiting Chemotherapy-Induced, Hematological Malignancies | 68 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07456982) |
| March 6, 2026 | NCT07456189 | The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of... | Institute of Hematology & Blood Diseases Hospital, China | Not applicable | Not yet recruiting | HSCT, Hematologic Cancer | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07456189) |
| March 2, 2026 | NCT07441967 | The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single... | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Hematologic Malignancies | 44 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441967) |
| February 27, 2026 | NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF... | Cancer Research UK | Phase 2/3 | Recruiting | Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms... | 30 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440290) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | China, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| February 17, 2026 | NCT07413991 | Expressive Writing Program Among Young Adults With Blood Cancer | Blood Cancer United | Not applicable | Active not recruiting | Hematologic Malignancy | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413991) |
| February 13, 2026 | NCT07409662 | Coverage and Cost of Care Links- Telehealth | Jean Edward | Not applicable | Completed | Financial Stress, Hematologic Cancer, Survivorship | 124 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409662) |
| February 11, 2026 | NCT07403812 | Assessing DCog Short for Neurotoxicity in CAR-T | Beth Israel Deaconess Medical Center | Not applicable | Recruiting | Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy, Immune Effector Cell Associated Neurotoxicity Syndrome | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403812) |
| January 26, 2026 | NCT07367997 | Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy | Jinnah Postgraduate Medical Centre | Not applicable | Completed | Cancer (Solid Tumors), Cancer and / or Hematological Malignancy | 100 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07367997) |
| January 23, 2026 | NCT07362732 | Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection | Sichuan University | Early phase 1 | Not yet recruiting | Hematological Malignancies | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362732) |
| January 23, 2026 | NCT07362602 | Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies | The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | Early phase 1 | Not yet recruiting | Hematological Malignancies | 47 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362602) |
| January 23, 2026 | NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative... | MPN Research Foundation | Observational | Recruiting | Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary... | 5,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362225) |
| January 22, 2026 | NCT07359859 | A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Hematologic Malignancies | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359859) |
| January 22, 2026 | NCT07358195 | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation | Massachusetts General Hospital | Early phase 1 | Recruiting | Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer | 3 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358195) |
| January 16, 2026 | NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | Orca Biosystems, Inc. | Not applicable | Available | Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndrome, Mixed Phenotype... | Not listed | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07346105) |
| January 5, 2026 | NCT07316907 | A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies | YANRU WANG | Phase 1 | Not yet recruiting | Hematologic Malignancies, Lymphoma | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07316907) |
| December 26, 2025 | NCT07305090 | Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease... | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Observational | Recruiting | Blood Cancer | 90 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305090) |
| December 24, 2025 | NCT07300735 | Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers | Alexandria University | Not applicable | Recruiting | Hematologic Malignancy, Neutropenia, Bone Pain | 88 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300735) |
| December 22, 2025 | NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors | Baylor College of Medicine | Phase 1 | Withdrawn | Lymphoma, Myeloma, Solid Tumors, Sarcoma, Kidney Cancer | 0 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297160) |
| December 19, 2025 | NCT07294300 | A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Relapsed/Refractory Hematological Malignancies | 124 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294300) |
| December 18, 2025 | NCT07292272 | Halt Aging in Survivors of Blood Cancers | University of Nebraska | Not applicable | Recruiting | Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia... | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292272) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 6 | July 1, 2026 |
| Tata Memorial Centre | 5 | July 24, 2026 |
| Ruijin Hospital | 4 | June 29, 2026 |
| National Cancer Institute (NCI) | 4 | April 13, 2026 |
| The First Affiliated Hospital of Soochow University | 3 | November 9, 2026 |
| Massachusetts General Hospital | 3 | October 21, 2026 |
| Assiut University | 3 | September 25, 2026 |
| Nanfang Hospital, Southern Medical University | 3 | August 13, 2026 |
| M.D. Anderson Cancer Center | 3 | August 4, 2026 |
| Memorial Sloan Kettering Cancer Center | 3 | January 22, 2026 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 3 | December 26, 2025 |
| Wake Forest University Health Sciences | 3 | October 2, 2025 |
| University Hospital, Caen | 2 | November 6, 2026 |
| Alexandria University | 2 | September 29, 2026 |
| Nanjing Miracle Biotechnology Co., Ltd. | 2 | September 9, 2026 |
| Tempus AI | 2 | August 10, 2026 |
| LucasBio | 2 | July 16, 2026 |
| City of Hope Medical Center | 2 | July 8, 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 | July 8, 2026 |
| Azienda USL Reggio Emilia - IRCCS | 2 | May 11, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 57 | October 26, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 47 | October 28, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 29 | November 6, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 20 | November 9, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 15 | October 27, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 9 | September 3, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 8 | July 8, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 4 | June 9, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 3 | November 6, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 65 | October 21, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 42 | September 9, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 16 | November 6, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 13 | October 6, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 12 | October 26, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 9 | October 7, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 5 | November 9, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 5 | October 23, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 5 | August 7, 2026 |
| [India](https://specstream.ai/data/clinical-trials/country/india) | 5 | July 24, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 5 | June 15, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 5 | June 15, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 4 | June 15, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 3 | September 29, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 3 | June 15, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 3 | June 15, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 3 | March 9, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 2 | October 26, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 2 | October 14, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 2 | September 10, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 2 | October 24, 2025 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 2 | September 15, 2025 |
| [Jordan](https://specstream.ai/data/clinical-trials/country/jordan) | 1 | October 28, 2026 |
| [Oman](https://specstream.ai/data/clinical-trials/country/oman) | 1 | October 28, 2026 |
| [Qatar](https://specstream.ai/data/clinical-trials/country/qatar) | 1 | October 28, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).